Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.

P Yotnda; H Firat; F Garcia-Pons; Z Garcia; G Gourru; J P Vernant; F A Lemonnier; V Leblond; P Langlade-Demoyen

doi:10.1172/JCI488

Unité d'Immunité Cellulaire Antivirale, Institut Pasteur, 75724 Paris, Cédex 15, France.

Find articles by Yotnda, P. in: PubMed | Google Scholar

Unité d'Immunité Cellulaire Antivirale, Institut Pasteur, 75724 Paris, Cédex 15, France.

Find articles by Firat, H. in: PubMed | Google Scholar

Unité d'Immunité Cellulaire Antivirale, Institut Pasteur, 75724 Paris, Cédex 15, France.

Find articles by Garcia-Pons, F. in: PubMed | Google Scholar

Unité d'Immunité Cellulaire Antivirale, Institut Pasteur, 75724 Paris, Cédex 15, France.

Find articles by Garcia, Z. in: PubMed | Google Scholar

Unité d'Immunité Cellulaire Antivirale, Institut Pasteur, 75724 Paris, Cédex 15, France.

Find articles by Gourru, G. in: PubMed | Google Scholar

Unité d'Immunité Cellulaire Antivirale, Institut Pasteur, 75724 Paris, Cédex 15, France.

Find articles by Vernant, J. in: PubMed | Google Scholar

Unité d'Immunité Cellulaire Antivirale, Institut Pasteur, 75724 Paris, Cédex 15, France.

Find articles by Lemonnier, F. in: PubMed | Google Scholar

Unité d'Immunité Cellulaire Antivirale, Institut Pasteur, 75724 Paris, Cédex 15, France.

Find articles by Leblond, V. in: PubMed | Google Scholar

Unité d'Immunité Cellulaire Antivirale, Institut Pasteur, 75724 Paris, Cédex 15, France.

Find articles by Langlade-Demoyen, P. in: PubMed | Google Scholar

Published in Volume 101, Issue 10 on May 15, 1998
J Clin Invest. 1998;101(10):2290–2296. https://doi.org/10.1172/JCI488.
© 1998 The American Society for Clinical Investigation

Published May 15, 1998 - Version history

Human chronic myelogenous leukemia (CML) is characterized by a translocation between chromosomes 9 and 22 that results in a BCR-ABL fusion gene coding for chimeric proteins. The junctional region of the BCR-ABLb3a2 molecule represents a potential leukemia-specific antigen which could be recognized by cytotoxic T lymphocytes (CTL). In fact, we identified a junctional nonapeptide (SSKALQRPV) which binds to HLA-A2.1 molecules. This peptide, as well as those binding to HLA-A3, -A11, and -B8 molecules (previously identified by others), elicits primary CTL responses in vitro from PBLs of both healthy donors and CML patients. Such CTL recognize HLA-matched, BCR-ABL-positive leukemic cells, implying efficient natural processing and presentation of these junctional peptides. Specific CTL were found at high frequency in 5 of 21 CML patients, suggesting that these epitopes are, to some extent, immunogenic in vivo during the course of the disease. These peptides could be useful for the development of specific immunotherapy in CML patients.

Version 1 (May 15, 1998): No description

Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.

P Yotnda, H Firat, F Garcia-Pons, Z Garcia, G Gourru, J P Vernant, F A Lemonnier, V Leblond, and P Langlade-Demoyen

Article tools

Metrics

Go to

Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.

P Yotnda, H Firat, F Garcia-Pons, Z Garcia, G Gourru, J P Vernant, F A Lemonnier, V Leblond, and P Langlade-Demoyen

Article tools

Metrics

Go to

Sign up for email alerts